Arthritogenic Igs
关节炎免疫球蛋白
基本信息
- 批准号:7022263
- 负责人:
- 金额:$ 36.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-03-01 至 2009-12-31
- 项目状态:已结题
- 来源:
- 关键词:antibody formationantibody receptorautoantigensclinical researchcomplement pathwaycomplement pathway regulationdisease /disorder etiologydisease /disorder modelgenetically modified animalsglucose 6 phosphate isomerasehuman subjectimmune compleximmunoglobulin structureimmunoglobulinsimmunopathologylaboratory mouseneutrophilrheumatoid arthritis
项目摘要
DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) is a chronic, progressive autoimmune disease directed at the synovial joints. Its etiology and pathogenesis remain controversial. A performant model of RA is provided by the K/BxN mouse, which spontaneously develops a disorder with striking similarities to the human one (though with some differences as well). Disease development in this model depends on combined T and B cell reactivity to the glycolytic enzyme glucose-6-phosphate isomerase, or GPI. Sera or anti-GPI antibodies (Abs) from arthritic K/BxN mice can rapidly, robustly and repeatedly transfer arthritis into healthy recipients. This system has permitted significant progress in dissecting the end-stage effector mechanisms that culminate in K/BxN arthritis - implicating inflammatory cytokines, a limited set of cell types, both Fc receptors and the complement network, and GPI-containing immune complexes. On the basis of these findings, a pathogenetic scenario capable of accounting for the joint specificity of this model has been constructed.
In this competing renewal application, three Specific Aims will be undertaken:
1. An assessment of the roles of un- or under-explored elements of the complement network in K/BxN serum-transferred arthritis.
2. An integration of the key molecular and cellular requirements for anti-GPI-induced arthritis, with a focus on neutrophil functions.
3. An exploration of the relevance of K/BxN disease mechanisms to human RA.
Results from these experiments should prove important from two perspectives: First, they will provide a deeper understanding of the end-stage effector mechanisms that come into play during K/BxN arthritis. Second, they will allow a more informed assessment of the relationship between K/BxN and human arthritis.
描述(由申请人提供):类风湿性关节炎(RA)是一种针对滑膜关节的慢性进行性自身免疫性疾病。其病因和发病机制仍有争议。K/BxN小鼠提供了一种表现良好的RA模型,它自发地发展出一种与人类疾病惊人相似的疾病(尽管也有一些差异)。该模型中的疾病发展取决于T和B细胞对糖酵解酶葡萄糖-6-磷酸异构酶或GPI的反应性。来自关节炎K/BxN小鼠的血清或抗GPI抗体(Abs)可以快速、稳健和重复地将关节炎转移到健康受体中。该系统已经允许在剖析最终导致K/BxN关节炎的终末期效应器机制方面取得重大进展-涉及炎性细胞因子、有限的一组细胞类型、Fc受体和补体网络以及含GPI的免疫复合物。在这些研究结果的基础上,已经构建了一个能够解释该模型的联合特异性的发病机制。
在此竞争性续期申请中,将实现三个特定目标:
1.未探索或未充分探索的补体网络元件在K/BxN血清转移性关节炎中的作用评估
2.抗GPI诱导的关节炎的关键分子和细胞要求的整合,重点是中性粒细胞功能。
3.探索K/BxN疾病机制与人类RA的相关性。
这些实验的结果应该从两个方面证明是重要的:首先,它们将提供对K/BxN关节炎期间发挥作用的终末期效应机制的更深入理解。其次,它们将允许对K/BxN与人类关节炎之间的关系进行更明智的评估。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DIANE J MATHIS其他文献
DIANE J MATHIS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DIANE J MATHIS', 18)}}的其他基金
Generation of a Cellular Atlas of Adipose Tissue in Mouse and Man
小鼠和人类脂肪组织细胞图谱的生成
- 批准号:
9906217 - 财政年份:2018
- 资助金额:
$ 36.09万 - 项目类别:
Adipose-issue Tregs: Important Players In The Immunological Control Of Metabolis
脂肪问题 Tregs:代谢免疫控制的重要参与者
- 批准号:
8677881 - 财政年份:2011
- 资助金额:
$ 36.09万 - 项目类别:
Adipose-tissue Tregs: important players in immunological control of metabolism
脂肪组织 Tregs:代谢免疫控制的重要参与者
- 批准号:
10398115 - 财政年份:2011
- 资助金额:
$ 36.09万 - 项目类别:
Adipose-tissue Tregs: important players in immunological control of metabolism
脂肪组织 Tregs:代谢免疫控制的重要参与者
- 批准号:
9815097 - 财政年份:2011
- 资助金额:
$ 36.09万 - 项目类别:
Adipose-issue Tregs: Important Players In The Immunological Control Of Metabolis
脂肪问题 Tregs:代谢免疫控制的重要参与者
- 批准号:
8478098 - 财政年份:2011
- 资助金额:
$ 36.09万 - 项目类别:
Adipose-tissue Tregs: important players in immunological control of metabolism
脂肪组织 Tregs:代谢免疫控制的重要参与者
- 批准号:
9980363 - 财政年份:2011
- 资助金额:
$ 36.09万 - 项目类别:
Adipose-tissue Tregs: important players in immunological control of metabolism
脂肪组织 Tregs:代谢免疫控制的重要参与者
- 批准号:
10585127 - 财政年份:2011
- 资助金额:
$ 36.09万 - 项目类别:
相似海外基金
Study on the mechanism of prolonged half-life of blood IgY by unique antibody receptor and its application to immune enhancement in birds
独特抗体受体延长血液IgY半衰期的机制研究及其在禽类免疫增强中的应用
- 批准号:
23H02361 - 财政年份:2023
- 资助金额:
$ 36.09万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Innate immune functions of the intracellular antibody receptor TRIM21
细胞内抗体受体 TRIM21 的先天免疫功能
- 批准号:
nhmrc : GNT1124162 - 财政年份:2017
- 资助金额:
$ 36.09万 - 项目类别:
Early Career Fellowships
Innate immune functions of the intracellular antibody receptor TRIM21
细胞内抗体受体 TRIM21 的先天免疫功能
- 批准号:
nhmrc : 1124162 - 财政年份:2017
- 资助金额:
$ 36.09万 - 项目类别:
Early Career Fellowships
Mechanism and engineering of IgG-based monoclonal antibody/receptor interactions
基于 IgG 的单克隆抗体/受体相互作用的机制和工程
- 批准号:
9300976 - 财政年份:2015
- 资助金额:
$ 36.09万 - 项目类别:
Mechanism and engineering of IgG-based monoclonal antibody/receptor interactions
基于 IgG 的单克隆抗体/受体相互作用的机制和工程
- 批准号:
9920805 - 财政年份:2015
- 资助金额:
$ 36.09万 - 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
- 批准号:
8900121 - 财政年份:2012
- 资助金额:
$ 36.09万 - 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
- 批准号:
8225814 - 财政年份:2012
- 资助金额:
$ 36.09万 - 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
- 批准号:
8699511 - 财政年份:2012
- 资助金额:
$ 36.09万 - 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
- 批准号:
8525355 - 财政年份:2012
- 资助金额:
$ 36.09万 - 项目类别:
Small Grants for Exploratory Research: Separation of Cells and Biological Macromolecules by Antibody Receptor Coated Magnetic Vesicles and Ferritin Conjugates
探索性研究小额资助:通过抗体受体包被的磁囊和铁蛋白缀合物分离细胞和生物大分子
- 批准号:
9115537 - 财政年份:1991
- 资助金额:
$ 36.09万 - 项目类别:
Standard Grant














{{item.name}}会员




